


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE COPY OF PAPERS  
ORIGINALLY FILED

Application No.: tba  
Filed: tba  
1<sup>st</sup> Inventor: H. ODAKA  
For: Pharmaceutical Composition For The  
Treatment of Diabetes  
Atty. Dkt. No. 2530 US1P

Art Unit: tba  
Examiner: tba  
Allowed:  
Batch:  
Paper No.:



Information Disclosure Statement

Commissioner for Patents  
Washington, D.C. 20231  
Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449. A legible copy of each listed reference has been previously submitted to the Patent Office in prior patent application Serial No. 09/380,059.

This information disclosure statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

For each non-English language reference listed on the attached Form PTO-1449, reference is made to the concise explanation attached thereto.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached Form PTO-1449 be returned in accordance with MPEP §9609.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, he is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated: October 29, 2001

(847) 383-3372  
(847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA

**BEST AVAILABLE COPY**

Page 1 of 4 FORM PTO 1449 (modified)				ATTY DOCKET NO.: 2530US1P		SERIAL NO.:	
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO:				APPLICANT: ODAKA Hiroyuki and YAMANE Masahiro			
				FILING DATE:		GROUP:	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO
	A1	EP 0749751-A	Dec. 27, '96				
	A2	EP 0516349-A	Dec. 2, '92				
	A3	WO 93/03724	Mar. 4, '93				
	A4	WO 97/27847	Aug. 7, '97				
<b>OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	A5		A. Okuno et al., "Effects of Thiazolidine Derivatives on Zucker Fatty Rat Adipose Tissue" <i>Diabetes Frontier</i> Vol. 8, 1997 pp. 499-501 (With its English translation)				
	A6		A.A. Kheir El-Din et al., "Possible Interactions of Some Anorexigenic Drugs..." <i>Egypt J. Pharm. Sci.</i> Vol. 29, No. 1-4, pp.355-366 (1988)				
EXAMINER:				DATE CONSIDERED:			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**BEST AVAILABLE COPY**